Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: J Cell Physiol. 2019 Oct 6;235(4):3731–3740. doi: 10.1002/jcp.29267

Figure 7: SOX2 depletion does not alter the responses of i-KD(SOX2)-C4-2B cells to enzalutamide.

Figure 7:

A. Responses of i-SOX2-LNCaP and i-SOX2-C4-2B cells to enzalutamide (10 μM) after 4 days of treatment. The growth of the control cells was set to 1. B. RT-qPCR analysis of SOX2 expression in i-KD(SOX2)-C4–2B cells after 48 hrs growth in the presence or absence of 500 ng/ml Dox. C. Growth of i-KD(SOX2)-C4–2B cells after 4 days in the presence or absence of 500 ng/ml Dox. D. Growth of parental C4–2B after 4 days in the presence or absence of 500 ng/ml Dox. E. Growth of i-KD(SOX2)-C4–2B cells after 4 days in the presence or absence of Dox (500 ng/ml) and the indicated concentrations of enzalutamide. To correct for inhibition of growth by SOX2 knockdown in the absence of enzalutamide, the growth of the cells in the presence and absence of Dox were each set to 1. This experiment was repeated at 250 ng/ml of Dox and same range of enzalutamide concentrations, and similar results were obtained. Error bars represent standard deviation; statistical significance was determined by a 2-tailed student’s t-test (***p<.005), NS: not statistically significant.